Leitlinien 2007 der Europäischen Gesellschaften für Hypertonie und Kardiologie - Was hat sich geändert?

Schlüsselwörter

Leitlinien - Hypertonie - Update - Endorganschäden - Behandlung

Key words

guidelines - hypertension - update - target organ damage - treatment

Literatur

• 1 Arima H, Chalmers J, Woodward M, Anderson C, Rodgers A, Davis S, Macmahon S, Neal B. PROGRESS Collaborative Group . Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial.  J Hypertens. 2006;  24 1201-8
• 2 Bigazzi R, Bianchi S, Baldari D, Campese V M. Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension.  J Hypertens. 1998;  16 1325-33
• 3 Braunwald E, Domanski M J, Fowler S E, Geller N L, Gersh B J, Hsia J, Pfeffer M A, Rice M M, Rosenberg Y D, Rouleau J L. PEACE Trial Investigators . Angiotensin-converting-enzyme inhibition in stable coronary artery disease.  N Engl J Med. 2004;  351 2058-68
• 4 Chobanian A V, Bakris G L, Black H R, Cushman W C, Green L A, Izzo Jr J L, Jones D W, Materson B J, Oparil S, Wright Jr J T, Roccella E J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.  JAMA. 2003;  289 2560-72
• 5 Deutsche Hochdruckliga e. V. - DHL - Deutsche Hypertonie Gesellschaft . Leitlinien zur Diagnostik und Therapie der arteriellen Hypertonie.  Nieren und Hochdruckkrankheiten. 2005;  34 481-498
• 6 Elliott W J, Meyer P M. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis.  Lancet. 2007;  369 (9557) 201-7 , Erratum in: Lancet 2007 May 5; 369 (9572): 1518
• 7 Fox K M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators . Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease (the EUROPA study).  Lancet. 2003;  362 782-8
• 8 Healey J S, Baranchuk A, Crystal E, Morillo C A. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.  J Am Coll Cardiol. 2005;  45 1832-9
• 9 Held C, Gerstein H C, Yusuf S, Zhao F, Hilbrich L, Anderson C, Sleight P, Teo K. ONTARGET/TRANSCEND Investigators . Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.  Circulation. 2007;  115 1371-5
• 10 Hillege H L, Fidler V, Diercks G F, van Gilst W H, de Zeeuw D, van Veldhuisen D J, Gans R O, Janssen W M, Grobbee D E, de Jong P E. Prevention of Renal and Vascular End Stage Disease (PREVEND) Study Group . Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population.  Circulation. 2002;  106 1777-82
• 11 Khan N, McAlister F A. Re-examining the efficacy of beta-blockers for the treatment of hypertension: a meta-analysis.  CMAJ. 2006;  174 1737-42 , Erratum in: CMAJ 2007; 176: 976
• 12 Lang R M, Bierig M, Devereux R B, Flachskampf F A, Foster E, Pellikka P A, Picard M H, Roman M J, Seward J, Shanewise J, Solomon S, Spencer K T, St John Sutton M, Stewart W. Recommendations for chamber quantification.  Eur J Echocardiogr. 2006;  7 79-108
• 13 Lubsen J, Wagener G, Kirwan B A, de Brouwer S, Poole-Wilson P A. ACTION (A Coronary disease Trial Investigating Outcome with Nifedipine GITS) investigators . Effect of long-acting nifedipine on mortality and cardiovascular morbidity in patients with symptomatic stable angina and hypertension: the ACTION trial.  J Hypertens. 2005;  23 641-8
• 14 Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty A M, Kjeldsen S E, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder R E, Boudier H A, Zanchetti A. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC).  J Hypertens. 2007;  25 1105-87
• 15 Messerli F H, Mancia G, Conti C R, Hewkin A C, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine C J. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous?.  Ann Intern Med. 2006;  144 884-93
• 16 Nissen S E, Tuzcu E M, Libby P, Thompson P D, Ghali M, Garza D, Berman L, Shi H, Buebendorf E, Topol E J. CAMELOT Investigators . Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure.  JAMA. 2004;  292 2217-25
• 17 Schmieder R, Kjeldsen S, Julius S, McInnes G T, Zanchetti A, Hua T. Reduced Incidence of new onset atrial fibrillation with angiotensin II receptor blockade: The Value-Trial.  J Hypertens. 2006;  24, Supp 4 S3
• 18 Top 10 papers published.  The Scientist. 2005;  19 26
• 19 Zanchetti A, Hansson L, Menard J, Leonetti G, Rahn K H, Warnold I, Wedel H. Risk assessment and treatment benefit in intensively treated hypertensive patients of the hypertension Optimal Treatment (HOT) study.  J Hypertens. 2001;  19 819-25